Is this you?
Request access for Atlanta Diabetes Associates with your @atlantadiabetes.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.
Intera lens
ICP 5Lift (cardio sample) 1.00Recruit soph 0
Quality Scorecard (1–100)
Overall66Recruit54Ops71Sponsor75Ther65
Performance (observed)
Historical trials
213
Completed
129
Terminated/Withdrawn
34
Completion rate
79%
Active now
48
Phase 2
37
Phase 3
107
Realized enrollment
411,307
First study year
2002
Years active
24
Match confidence
high
Enrollment velocity (inf)
17,138
Therapeutic
Areas
Cardiometabolic (cardiology/endocrinology/hepatology/renal, per ClinicalTrials.gov)
Breadth (conditions)
112
States
Georgia
Recruitment (web observed)
Capability notes
4 active recruiting cardiometabolic trials (ClinicalTrials.gov)
Relationships
Sponsors
Medtronic MiniMed, Inc.; Eli Lilly and Company; Novo Nordisk A/S; Boehringer Ingelheim; Mannkind Corporation; Pfizer
CROs
Covance; ICON Clinical Research; MacroGenics; Medpace, Inc.; PPD, Part of Thermo Fisher Scientific; Parexel
Owner / parent
Unknown
Capacity & people
Investigators
—
Coordinators
—
Emails
amaxson@atlantadiabetes.com
Tech & DCT
Builds tech
Unknown
Tech stack
Unknown
Recruiting visible
Y
Notes
Surfaced via ClinicalTrials.gov mining (not on curated lists). 4 active recruiting cardiometabolic trials across 1 location(s). Actively-recruiting independent site = warm Intera lead; website/leadership not yet verified.
Recommendation features (sample indication)
Ind fit 1.00Liftability 1.00Overall66
FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.